Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

Enhertu is an antibody-drug conjugate (ADC) designed to treat patients with certain types of breast cancer. Credit: Dikushin Dmitry via Shutterstock. The UK’s National Institute for Health and ...

Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move that will boost the British drugmaker’s sales in the country in the midst ...

The latest health news includes China allowing foreign-owned hospitals in major cities, and the inclusion of AstraZeneca's ...

The UK’s National Institute for Health and Care Excellence (NICE) has once again rejected Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu (trastuzumab deruxtecan), marking the third ...

China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...